Ensign Peak Advisors
AZN icon

Ensign Peak Advisors’s AstraZeneca AZN Stock Holding History

Ensign Peak Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1M Buy
54,111
+350
+0.7% +$65.8K 0.02% 435
2026
Q1 		$10.4M Buy
+53,761
New +$10.4M 0.02% 401
2024
Q1 		– Sell
-359,341
Closed -$48.4M – 1726
2023
Q4 		$48.4M Sell
359,341
-932,996
-72% -$121M 0.1% 190
2023
Q3 		$175M Buy
1,292,337
+45,409
+4% +$6.2M 0.37% 62
2023
Q2 		$178M Buy
1,246,928
+72,969
+6% +$10.7M 0.36% 62
2023
Q1 		$163M Buy
1,173,959
+109,480
+10% +$14.7M 0.35% 73
2022
Q4 		$144M Buy
1,064,479
+10,227
+1% +$1.28M 0.33% 79
2022
Q3 		$116M Sell
1,054,252
-277,994
-21% -$35.3M 0.29% 82
2022
Q2 		$176M Buy
1,332,246
+133,077
+11% +$17.5M 0.42% 60
2022
Q1 		$159M Buy
1,199,169
+770,757
+180% +$92.4M 0.32% 71
2021
Q4 		$49.9M Buy
428,412
+343,348
+404% +$40.4M 0.1% 186
2021
Q3 		$10.2M Buy
85,064
+2,709
+3% +$315K 0.02% 427
2021
Q2 		$9.87M Buy
82,355
+8
+0% +$878 0.02% 430
2021
Q1 		$8.19M Sell
82,347
-5,140
-6% -$517K 0.02% 474
2020
Q4 		$8.75M Buy
+87,487
New +$9.27M 0.02% 448
2020
Q3 		– Sell
-92,533
Closed -$9.79M – 1745
2020
Q2 		$9.79M Buy
92,533
+86,243
+1,371% +$8.91M 0.03% 431
2020
Q1 		$562K Sell
6,290
-22,134
-78% -$2.08M ﹤0.01% 1362
2019
Q4 		$2.83M Buy
+28,424
New +$2.68M 0.01% 883

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ensign Peak Advisors's AZN Position: Q2 2026 in Review

Ensign Peak Advisors increased its AstraZeneca (AZN) stake by 0.65% in Q2 2026, buying an estimated $65.8K and bringing the position to 54,111 shares worth $10.1M. The position accounts for 0.02% of the portfolio, ranked #435.

Ensign Peak Advisors first reported a position in AZN in Q4 2019 and has held it in 18 quarters since. The position peaked at $178M in Q2 2023. 1,501 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Ensign Peak Advisors held 54,111 shares of AstraZeneca worth $10.1M as of Q2 2026.
  • Ensign Peak Advisors bought 350 AstraZeneca shares in Q2 2026, an estimated $65.8K.
  • AstraZeneca made up 0.02% of Ensign Peak Advisors's portfolio in Q2 2026, its #435 holding.
  • Ensign Peak Advisors first reported a position in AstraZeneca in Q4 2019 and has held it in 18 quarters since.
  • Ensign Peak Advisors's AstraZeneca position peaked at $178M in Q2 2023.
  • 1,501 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.